AMED - Amedisys, Inc.
| Previous Close | 115.64 |
| Open | 115.47 |
| Bid | 112.17 x 800 |
| Ask | 125.00 x 800 |
| Day's Range | 115.18 - 120.07 |
| 52 Week Range | 63.00 - 140.91 |
| Volume | 477,976 |
| Avg. Volume | 439,050 |
| Market Cap | 3.752B |
| Beta (3Y Monthly) | 1.24 |
| PE Ratio (TTM) | 33.02 |
| EPS (TTM) | 3.55 |
| Earnings Date | May 6, 2019 - May 10, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 134.30 |
- Zacks•3 days ago
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
Chemed (CHE) is expected to benefit from the launch of its VITAS Healthcare Inpatient Hospice Unit.
- Simply Wall St.•4 days ago
A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)
Today we will run through one way of estimating the intrinsic value of Amedisys, Inc. (NASDAQ:AMED) by taking the foreast future cash flows of the company and discounting them back to today's value. I will be using the Discoun...
- Zacks•4 days ago
Medidata Launches Acorn Artificial Intelligence Company
Driven by Medidata's (MDSO) standardized clinical data storehouse, and operating on its pioneering platform, Acorn AI is set to become one of the premier AI companies in the field of life sciences.
- Zacks•5 days ago
Hologic's Diagnostics Grows Strong, Escalating Costs a Woe
To fortify its product portfolio, Hologic (HOLX) is working on innovations and product introductions. On this front, Cynosure's R&D pipeline stays robust.
- GlobeNewswire•6 days ago
Amedisys Announces First Quarter Earnings Release and Conference Call Date
Amedisys, Inc. (AMED), announced today that it will report results for the first quarter ended March 31, 2019, after the market closes on April 30, 2019. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on May 1, 2019. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll).
- Zacks•9 days ago
ResMed Launches AirFit P30i Nasal Pillows Mask in the US
ResMed (RMD) to expand its portfolio of sleep apnea devices on the back of AirFit P30i nasal pillows mask.
- Zacks•9 days ago
Medtronic's (MDT) Study Shows Positive Results of TDD Use (revised)
The outcomes of the study demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.
- Zacks•9 days ago
Zacks.com featured expert Kevin Matras highlights: Medifast, Foot Locker, Amedisys, Comfort Systems and CarGurus
Zacks.com featured expert Kevin Matras highlights: Medifast, Foot Locker, Amedisys, Comfort Systems and CarGurus
- Zacks•10 days ago
Zacks.com featured expert Kevin Matras highlights: WellCare Health Plans, Domtar, Amedysis, Fastenal and DMC Global
Zacks.com featured expert Kevin Matras highlights: WellCare Health Plans, Domtar, Amedysis, Fastenal and DMC Global
- Zacks•10 days ago
ResMed's Brightree Widens ReSupply Solution Usage for HME
Resmed's (RMD) Brightree ReSupply is a scalable and automated solution that comprises live-agent inbound and outbound calls for more private interaction with patients and email reminder capabilities.
- Zacks•10 days ago
Looking for a Growth Stock? 3 Reasons Why Amedisys (AMED) is a Solid Choice
Amedisys (AMED) could produce exceptional returns because of its solid growth attributes.
- Zacks•10 days ago
5 Top-Ranked Stocks to Play DuPont Analysis
Have more faith in DuPont analysis than simple ROE calculation? Bet on these five stocks.
- Zacks•10 days ago
Walgreens Partners With VillageMD to Offer Primary Healthcare
This joint venture marks Walgreens' (WBA) commitment toward enabling access to affordable healthcare and creating neighborhood health destinations.
- Zacks•11 days ago
Buy These 5 Low Leverage Stocks to Avoid the Perils of Debt
Before investing blindly in a stock exhibiting solid growth traits, one should consider the extent of its leverage in order to avoid falling into debt traps.
- Zacks•11 days ago
Here's Why You Should Hold on to DaVita (DVA) Stock Now
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, rising expenses remain a dampener.
- Zacks•11 days ago
Medtronic's (MDT) Study Shows Positive Results of TDD Use
The outcomes of the study, conducted by Medtronic (MDT), demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.
- Zacks•11 days ago
Walgreens' Weak Market Trends a Woe, Strategic Deals to Aid
Walgreens Boots (WBA) currently endeavors to redress certain areas of operational weakness and reinforces its managerial competence to drive operating efficiency with a resolute focus.
- Zacks•11 days ago
Medtronic (MDT) Inks Value-Based Deal for Guardian Connect
Medtronic's (MDT) Guardian Connect system can now be accessed via a Blue Cross and Blue Shield of Minnesota member's pharmacy benefit.
- Markit•12 days ago
See what the IHS Markit Score report has to say about Amedisys Inc.
Amedisys Inc NASDAQ/NGS:AMEDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for AMED with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold AMED had net inflows of $2.24 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•12 days ago
Bio-Rad's (BIO) IH-500 System Secures 510(K) From the FDA
The regulatory go-ahead is in line with Bio-Rad's (BIO) strategy of strengthening in the transfusion medicine market of the United States.
- Zacks•13 days ago
Intersect ENT Grows on Product Launch Amid Pricing Pressure
Intersect ENT (XENT) recently finishes the ENCORE Study, which is a small 50-patient open label program, designed to evaluate the safety of the repeat use of SINUVA.
- Zacks•13 days ago
Natus Medical to Divest Medix for Focusing on Core Business
Per Natus Medical (BABY), this deal is strategically aligned with its business as besides concentrating on its core products, this sell-off will lead to planned investment in the high-growth markets.
- Zacks•13 days ago
Medtronic's New Data for HVAD System to Boost CRHF Segment
Medtronic's (MDT) latest data is expected to boost top-line contributions from the HeartWare HVAD System within the CRHF suite.
- Zacks•13 days ago
Orthofix (OFIX) Reports Encouraging M6-C Disc Study Results
The primary goal of the study was to assess the safety and efficacy of Orthofix's (OFX) M6-C artificial cervical disc in comparison to ACDF treatment.
- Zacks•16 days ago
ResMed's (RMD) Brightree Unveils Analytics Platform for HME
The Analytics arm, launched by ResMed (RMD) unit Brightree, provides workflow insights and facilitates KPI tracking plus peer benchmarking without the users having to amass the data themselves.
